Core Viewpoint - The Chinese innovative drug "Jiuqi Yi," known for its development as an Alzheimer's treatment, is facing production suspension due to the expiration of its drug registration certificate and failure to complete renewal approval on time [1][2]. Group 1: Company Situation - Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd. announced that as of May 30, 2025, relevant positions for "Jiuqi Yi" have been suspended [1]. - The company has been actively communicating with regulatory authorities and participated in expert review meetings in March and April of this year [1]. - The company has accumulated significant research data and patient feedback, indicating a strong demand for the drug despite its current challenges [1]. Group 2: Production Facilities - The production base in Qingpu is still operational but primarily focuses on the production of other products, with the production line for "Jiuqi Yi" already suspended [2]. - The investment in the Shanghai Pudong production base totals 1.227 billion yuan, which was expected to be completed by the end of 2024, but has not been utilized since its construction [2]. - The lack of operation at the Pudong facility is attributed to the expiration of "Jiuqi Yi's" registration certificate and the company's current financial difficulties [2].

Core Viewpoint - The drug Gantoret Sodium Capsule (brand name: Jiuyi) for Alzheimer's disease has become scarce, leading to widespread concern about the difficulties patients face in obtaining medication [2][4][5] Group 1: Supply Issues - Since 2025, Gantoret Sodium Capsule has faced prescription difficulties in hospitals and supply shortages on online platforms [4][5] - The manufacturer, Green Valley Pharmaceutical Technology, acknowledged the supply issues and is in communication with relevant authorities to address the situation [2][4] - Reports indicate that the drug's market price has increased by approximately 40% in recent months, with some pharmacies listing prices as high as 5000 yuan per box [5][6] Group 2: Market Dynamics - The drug was first approved for conditional listing in November 2019 and officially launched in December 2019, allowing patients to purchase it with a doctor's prescription [4][6] - The initial price of the drug was set at 895 yuan per box, but it was later included in the national medical insurance directory, reducing the price to 296 yuan per box [6][7] - The current monthly cost for patients using Gantoret Sodium is approximately 1184 yuan, significantly lower than the combined cost of traditional treatments [6][7] Group 3: Disease Context - Alzheimer's disease is a major neurodegenerative condition affecting over 55 million people globally, with China having the highest number of patients [8] - The treatment options for Alzheimer's disease are limited, with Gantoret Sodium being one of the few drugs that can improve cognitive function without worsening the condition [8][9] - The drug was conditionally approved due to the urgent need for treatment options, despite some initial concerns regarding long-term safety data [9]